内容紹介
Summary
We reviewed our clinical experience of olaparib treatment for patients with platinum—sensitive recurrent ovarian, fallopian tube, and peritoneal cancer. Of the 10 cases, the primary sites of cancer were the ovaries, fallopian tubes, and peritoneum in 7, 1 and 2 cases, respectively. The median period of treatment administration was 10 months. The observed Grade 3 or 4 adverse events as per the Common Terminology Criteria for Adverse Events version 4.0 were:anemia, leukopenia and neutropenia in 4, 4 and 3 cases, respectively. Eight cases needed treatment to be interrupted, and 5 cases required a reduction in dose. Three patients were treated for more than 12 months, while the others had to discontinue due to disease progression. However, none of the patients had to discontinue treatment due to adverse events. Therefore, it appears that olaparib can be safely used despite some patients requiring a withdrawal or reduction in treatment.
要旨
当院におけるプラチナ感受性再発卵巣癌(以下,再発卵巣癌),卵管癌,原発性腹膜癌に対するolaparib使用に関する安全性,有効性を後方視的に検討した。内訳は再発卵巣癌7例,卵管癌1例,原発性腹膜癌2例の計10例であった。Grade 3以上の有害事象(CTCAE v4.0)の頻度は,貧血4例(40%),白血球減少症4例(40%),好中球減少症が3例(30%)であった。8例(80%)休薬,5例(50%)に減量が必要であったが,有害事象による治療中止例は認めなかった。投与期間の中央値10か月で,12か月以上の投与継続症例は3例あり,中止に至った7例はすべて病勢進行によるものであり,有害事象による中止例を認めなかった。olaparibは適切に休薬,減量を行うことにより安全に使用可能であった。
目次
We reviewed our clinical experience of olaparib treatment for patients with platinum—sensitive recurrent ovarian, fallopian tube, and peritoneal cancer. Of the 10 cases, the primary sites of cancer were the ovaries, fallopian tubes, and peritoneum in 7, 1 and 2 cases, respectively. The median period of treatment administration was 10 months. The observed Grade 3 or 4 adverse events as per the Common Terminology Criteria for Adverse Events version 4.0 were:anemia, leukopenia and neutropenia in 4, 4 and 3 cases, respectively. Eight cases needed treatment to be interrupted, and 5 cases required a reduction in dose. Three patients were treated for more than 12 months, while the others had to discontinue due to disease progression. However, none of the patients had to discontinue treatment due to adverse events. Therefore, it appears that olaparib can be safely used despite some patients requiring a withdrawal or reduction in treatment.
要旨
当院におけるプラチナ感受性再発卵巣癌(以下,再発卵巣癌),卵管癌,原発性腹膜癌に対するolaparib使用に関する安全性,有効性を後方視的に検討した。内訳は再発卵巣癌7例,卵管癌1例,原発性腹膜癌2例の計10例であった。Grade 3以上の有害事象(CTCAE v4.0)の頻度は,貧血4例(40%),白血球減少症4例(40%),好中球減少症が3例(30%)であった。8例(80%)休薬,5例(50%)に減量が必要であったが,有害事象による治療中止例は認めなかった。投与期間の中央値10か月で,12か月以上の投与継続症例は3例あり,中止に至った7例はすべて病勢進行によるものであり,有害事象による中止例を認めなかった。olaparibは適切に休薬,減量を行うことにより安全に使用可能であった。